INNOVATION ARTICLES
-
Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies
Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.
-
The Future Of Cancer Drug Discovery Is Targeted Immune Activation
Using targeted delivery systems to generate therapeutic agents directly within tumors has implications for how oncology drugs are discovered and developed.
-
A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials
CSB-001, Claris Bio’s eye drop for limbal stem cell deficiency, could offer a non-surgical way to improve vision, slow vision loss, and reshape LSCD care.
-
Emerging Fields In Immunology: New Frontiers For Therapeutic Discovery
Immunology has expanded into several specialized domains as our understanding of the immune system has grown.
-
Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections
Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.
-
From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2)
Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.
INNOVATION ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
Explore strategies for securing recombinant proteins while addressing supply continuity, batch consistency, scale-up challenges, and quality requirements for clinical validation and commercialization.
-
Overcome biomanufacturing tradeoffs with expression strategies that enhance stability, scalability, and production consistency.
-
Growing demand for cell and gene therapies is increasing pressure on cytokine production. Explore interleukin manufacturing, quality, consistency, safety, scalability, and supply reliability.
-
Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.
-
See how expression hosts affect recombinant EPO glycosylation, bioactivity, and consistency, with reproducible N-glycan profiles and absence of α1,3-linked fucosylation.
-
Explore how D. mel-derived human prolactin (hPRL) compares with hPRL expressed in E. coli and HEK293 cells through detailed physico-chemical and biological characterization.
INNOVATION SOLUTIONS
-
Overcome protein expression bottlenecks with a scalable insect-based platform that delivers faster development, predictable scale-up, and consistent manufacturing.
-
Produce recombinant proteins at scale with stable expression, flexible batch sizes, and streamlined manufacturing.
-
Capturing dynamic conformational states is key to target druggability. Advanced EPR spectroscopy delivers nanometer-resolution measurements for complex structural biology.
-
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
Curia’s in vivo Discovery Immunology team offers high-performance hybridoma-based technologies to help clients discover great antibodies that make a difference.
-
Curia offers phage and eukaryotic-based yeast display platforms for in vitro discovery and engineering of potent antibody candidates for therapeutic or diagnostic use. High-affinity functional antibodies are routinely selected against a wide range of conventional or challenging targets (e.g. GPCRs) using customized or in-licensed state-of-the-art libraries.
-
Curia has extensive experience with constructing and producing antibodies in our mammalian platforms.
-
Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development.
-
Our collaborative approach, proven track record, and deep technical expertise enable us to efficiently advance promising candidates, reduce development risk, and help transform innovative ideas into successful therapeutic realities.
-
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
Make the most of your molecule with integrated antibody discovery, engineering, and production capabilities designed to accelerate lead identification and optimization.
-
The Antibody Center at Curia provides end-to-end services in antibody discovery, engineering, and development.
-
Our Biologics services provide comprehensive Molecular Biology services at facilities in California and Massachusetts, offering a variety of services.
-
Curia has decades of experience in recombinant protein production.